Roflumilast (Zoryve) vs Roflumilast (Zoryve foam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
Roflumilast (Zoryve)
Marketed by Arcutis Biotherapeutics and partners
NCT06648772 · Phase 3 · completed
The study randomly assigned 190 participants to roflumilast cream or vehicle cream and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a clinical psoriasis severity measure, but whether that endpoint was met cannot be determined because results are not available.
Next expected readout: July 2027 · NCT07725822 (registry estimate)
Reported efficacy
Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%) (met)
Result source: NCT04211389
Roflumilast (Zoryve foam)
Marketed by Arcutis Biotherapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Roflumilast (Zoryve) | Roflumilast (Zoryve foam) |
|---|---|---|
| PASI 75 | 41.6% vs 7.6%+34 vs placeboNCT042113639 other results
| 50.1% vs 16.8%+33.3 vs placeboNCT05028582 |
| PASI 90 | 22.4% vs 2.3%+20.1 vs placeboNCT042113639 other results
| —Not reported |
| PASI 100 | —Not posted · NCT06648772 | —Not reported |
| sPGA 0/1 | —Not posted · NCT06648772 | —Not reported |
| DLQI, change | -2.6 vs -1.4−1.2 vs placeboNCT036382587 other results
| —Not reported |
PASI 75
- Roflumilast (Zoryve)
- 41.6% vs 7.6%+34 vs placeboNCT04211363
9 other results
- 39% vs 5.3% NCT04211389
- 31.3% vs 13.2% NCT03638258
- 23% vs 13.2% NCT03638258
- 24.1% vs 9.6% NCT03638258
- 22.2% vs 9.6% NCT03638258
- 13.3% vs 10.5% NCT03638258
- 7.6% vs 10.5% NCT03638258
- 34.1% vs 16% NCT03638258
- 31.1% vs 16% NCT03638258
- Roflumilast (Zoryve foam)
- 50.1% vs 16.8%+33.3 vs placeboNCT05028582
PASI 90
- Roflumilast (Zoryve)
- 22.4% vs 2.3%+20.1 vs placeboNCT04211363
9 other results
- 15.5% vs 2% NCT04211389
- 20.6% vs 7.8% NCT03638258
- 13.7% vs 7.8% NCT03638258
- 16.9% vs 6% NCT03638258
- 7.4% vs 6% NCT03638258
- 14.3% vs 3.2% NCT03638258
- 2.3% vs 3.2% NCT03638258
- 6% vs 2.3% NCT03638258
- 1.3% vs 2.3% NCT03638258
- Roflumilast (Zoryve foam)
- —Not reported
PASI 100
- Roflumilast (Zoryve)
- —Not posted · NCT06648772
- Roflumilast (Zoryve foam)
- —Not reported
sPGA 0/1
- Roflumilast (Zoryve)
- —Not posted · NCT06648772
- Roflumilast (Zoryve foam)
- —Not reported
DLQI, change
- Roflumilast (Zoryve)
- -2.6 vs -1.4−1.2 vs placeboNCT03638258
7 other results
- -4.2 vs -1.4 NCT03638258
- -2.6 vs -1.6 NCT03638258
- -3.5 vs -1.6 NCT03638258
- -2.6 vs -1.8 NCT03638258
- -3.1 vs -1.8 NCT03638258
- -2.2 vs -1.9 NCT03638258
- -2.3 vs -1.9 NCT03638258
- Roflumilast (Zoryve foam)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Roflumilast (Zoryve): 6 of 6 rows · Roflumilast (Zoryve foam): 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Roflumilast (Zoryve) Rows use multiple source trials | Roflumilast (Zoryve foam) Rows use multiple source trials |
|---|---|---|
| PASI absolute change · score Induction | -68.03 vs -13.65 placebo score @ 12wk0.15%a,b,c,d,e NCT03638258 · Phase 2 · registry result, not featured evidence show 1 more dose-59.48 vs -13.65 placebo score @ 12wk0.3% NCT03638258 · Phase 2 · registry result, not featured evidence | -2.31 vs -1.03 placebo score @ 2wk0.3% foamb,c,d,e NCT05028582 · Phase 3 |
| PSD absolute change · score Induction | -49.3 vs -22.8 placebo score @ 8wk0.3% creamf,g,d NCT04211389 · Phase 3 | -55 vs -27.5 placebo score @ 8wkf,g,d NCT04128007 · Phase 2 |
| Dropout rate | 10.8%0.3% creamh NCT04211363 · Phase 3 show 10 more results9%0.3% cream NCT04211389 · Phase 3 0%0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence 0%0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 28.7%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 21.6%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 8%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence —0.3% NCT03638258 · Phase 2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence | 11%0.3% foamh NCT05028582 · Phase 3 show 1 more result11.5% NCT04128007 · Phase 2 |
| Discontinued due to AEs | 1.7%0.3% creamh NCT04211363 · Phase 3 show 10 more results0.3%0.3% cream NCT04211389 · Phase 3 —0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence —0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 4.8%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 2%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 0%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence —0.3% NCT03638258 · Phase 2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence | 1.8%0.3% foamh NCT05028582 · Phase 3 show 1 more result2.5% NCT04128007 · Phase 2 |
| Serious AEs | 0.7%0.3% creamh NCT04211363 · Phase 3 show 10 more results0%0.3% cream NCT04211389 · Phase 3 0%0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence 0%0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 3.5%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 2%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 0.9%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence 0.9%0.3% NCT03638258 · Phase 2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence 0%0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence | 0.7%0.3% foamh NCT05028582 · Phase 3 show 1 more result0.5% NCT04128007 · Phase 2 |
| Most frequent reported AEs | show 8 more results0.3% cream application site pain 5% back pain 5% candida infection 5% NCT04655313 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 6.5% NCT03764475 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 6.9% NCT03764475 · Phase 2 · registry result, not featured evidence 0.15% upper respiratory tract infection 6.4% (placebo 0%) NCT03638258 · Phase 2 · registry result, not featured evidence 0.3% upper respiratory tract infection 7.3% (placebo 0%) NCT03638258 · Phase 2 · registry result, not featured evidence 0.5% candiduria 12.5% (placebo 0%) application site erythema 0% (placebo 12.9%) application site pain 0% (placebo 16.1%) NCT03392168 · Phase 1/2 · registry result, not featured evidence 0.15% nasopharyngitis 7.1% (placebo 0%) application site erythema 3.6% (placebo 12.9%) application site pain 3.6% (placebo 16.1%) NCT03392168 · Phase 1/2 · registry result, not featured evidence 0.5% application site erythema 13.3% (placebo 12.9%) application site pain 6.7% (placebo 16.1%) nasopharyngitis 6.7% (placebo 0%) NCT03392168 · Phase 1/2 · registry result, not featured evidence | — |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 12 weeks versus 2 weeks.
- fTrial phases differ: Phase 3 versus Phase 2.
- gPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
- hPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Roflumilast (Zoryve)
show 1 more result
show 1 more result
show 9 more results
show 1 more result
show 2 more results
show 2 more results
show 15 more results
show 1 more result
show 7 more results
show 7 more results
+ 7 further endpoints in the CSV export.
Roflumilast (Zoryve foam)
show 3 more results
show 1 more result
show 5 more results
show 2 more results
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Roflumilast (Zoryve)'s landscape · Roflumilast (Zoryve foam)'s landscape